TG Therapeutics
TGTX
237 hedge funds and large institutions have $3.73B invested in TG Therapeutics in 2021 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 88 increasing their positions, 70 reducing their positions, and 47 closing their positions.
26% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 70
4% less first-time investments, than exits
New positions opened: 45 | Existing positions closed: 47
1% less funds holding
Funds holding: 240 → 237 (-3)
2.26% less ownership
Funds ownership: 70.29% → 68.03% (-2.3%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
22% less capital invested
Capital invested by funds: $4.76B → $3.73B (-$1.03B)
26% less call options, than puts
Call options by funds: $61.6M | Put options by funds: $83.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$64.4M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$40M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$27.8M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$23.6M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$73.4M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$50.8M |
| 3 |
BlackRock
New York
|
-$37.2M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$32.4M |
| 5 |
AG
Artal Group
Luxembourg
|
-$27.5M |
TGTX Hedge Fund Activity: Q2 2021 in Review
237 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q2 2021, worth a combined $3.73B — down 22% from $4.76B a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of TGTX and 45 opened new positions — a net loss of 2 holders — while 70 trimmed existing stakes and 88 added.
The largest buyer was Westfield Capital Management, opening a new position worth an estimated $64.4M. The largest seller was Lord, Abbett & Co, cutting an estimated $73.4M.
- 237 institutional investors held TG Therapeutics (TGTX) as of Q2 2021, down from 240 in Q1 2021.
- Funds reported $3.73B of TG Therapeutics stock for Q2 2021, down 22% quarter-over-quarter.
- 45 funds opened new TG Therapeutics positions in Q2 2021 and 47 closed out, a net change of -2 holders.
- The largest TG Therapeutics buyer in Q2 2021 was Westfield Capital Management, an estimated $64.4M added.
- The largest TG Therapeutics seller in Q2 2021 was Lord, Abbett & Co, an estimated $73.4M sold.
Based on aggregated 13F filings for Q2 2021.